Greenwich LifeSciences (NASDAQ:GLSI) Releases Earnings Results, Misses Expectations By $0.40 EPS

Greenwich LifeSciences (NASDAQ:GLSI) announced its earnings results on Tuesday. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.40), Zacks reports.

Greenwich LifeSciences Stock Down 3.6 %

Shares of GLSI stock opened at $8.95 on Wednesday. The business has a fifty day simple moving average of $11.07 and a 200 day simple moving average of $12.47. The company has a market cap of $117.65 million, a P/E ratio of -11.19 and a beta of 1.76. Greenwich LifeSciences has a twelve month low of $8.06 and a twelve month high of $18.75.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of Greenwich LifeSciences in a research report on Tuesday, February 11th.

Insider Buying and Selling at Greenwich LifeSciences

In related news, CEO Snehal Patel bought 3,600 shares of the firm’s stock in a transaction on Monday, April 7th. The shares were purchased at an average price of $9.10 per share, with a total value of $32,760.00. Following the completion of the purchase, the chief executive officer now owns 5,561,602 shares in the company, valued at $50,610,578.20. This represents a 0.06 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 51.67% of the company’s stock.

Institutional Trading of Greenwich LifeSciences

An institutional investor recently raised its position in Greenwich LifeSciences stock. Bank of America Corp DE lifted its position in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 22.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,262 shares of the company’s stock after purchasing an additional 1,322 shares during the quarter. Bank of America Corp DE owned 0.06% of Greenwich LifeSciences worth $82,000 at the end of the most recent reporting period. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.